Ipsen: Oddo BHF raises target price
(CercleFinance.com) - Oddo BHF maintains its neutral rating on Ipsen shares, faising its target price from E120 to E125, ahead of the company's earnings release on 13 February.
The analyst anticipates Q4 sales of E895m (+11%e), (css: E878m) or E3388m for the full year (+8.3%). We estimate OP at E1061m vs. E1001m in 2023, i.e. 31.3% vs. 32% the previous year, Oddo BHF says, which believes that Ipsen should exceed its guidance for the 3rd year running.
Valuation is one of the attractions of the stock, the broker notes, which points out that the recent good price performance is essentially due to expectations for Somatuline in H2 2024.
The market is likely to fear a decline in Somatuline sales in 2025, but at the same time, the downside seems limited given the valuation, Oddo BHF concludes.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The analyst anticipates Q4 sales of E895m (+11%e), (css: E878m) or E3388m for the full year (+8.3%). We estimate OP at E1061m vs. E1001m in 2023, i.e. 31.3% vs. 32% the previous year, Oddo BHF says, which believes that Ipsen should exceed its guidance for the 3rd year running.
Valuation is one of the attractions of the stock, the broker notes, which points out that the recent good price performance is essentially due to expectations for Somatuline in H2 2024.
The market is likely to fear a decline in Somatuline sales in 2025, but at the same time, the downside seems limited given the valuation, Oddo BHF concludes.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.